Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.90 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.90 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.90 |
| ▸ | PDE2A | O00408 | 1/20 | 0.75 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.75 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.75 |
| ▸ | PDE6D | O43924 | 1/20 | 0.75 |
| ▸ | PDE8A | O60658 | 1/20 | 0.75 |
| ▸ | PDE9A | O76083 | 1/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
| ▸ | PDE6A | P16499 | 1/20 | 0.75 |
| ▸ | PDE6G | P18545 | 1/20 | 0.75 |
| ▸ | PDE4A | P27815 | 1/20 | 0.75 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.75 |
| ▸ | PDE6B | P35913 | 1/20 | 0.75 |
| ▸ | PDE6C | P51160 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31202702 | 1.00 | PDE5A (0.90) | PDE5APDE3BPDE3APDE2AABCC4 | |
| Lodenafil SCHEMBL31202790 | 0.95 | PDE5A (1.00) | PDE5APDE3BPDE3APDE2AABCC4 | |
| Lodenafil SCHEMBL1058 | 0.95 | PDE5A (1.00) | PDE5APDE3BPDE3APDE2AABCC4 | |
| SCHEMBL31202613 | 0.93 | PDE5A (0.90) | PDE5APDE3BPDE3APDE2AABCC4 | |
| SCHEMBL439392 | 0.93 | PDE5A (0.78) | PDE5APDE3BPDE3APDE2AABCC4 | |
| SCHEMBL6716971 | 0.92 | PDE5A (0.76) | PDE5APDE3BPDE3APDE2AABCC4 | |
| SCHEMBL28417921 | 0.92 | PDE5A (0.89) | PDE5APDE3BPDE3APDE2AABCC4 | |
| SCHEMBL5010426 | 0.89 | PDE5A (0.90) | PDE5APDE3BPDE3APDE2AABCC4 | |
| SCHEMBL997 | 0.89 | PDE5A (0.89) | PDE5APDE3BPDE3APDE2AABCC4 | |
| SCHEMBL6332389 | 0.89 | PDE5A (0.72) | PDE5APDE3BPDE3APDE2AABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716298-B2 | Composition for reducing skin wrinkles including PDE5 inhibitor | SK CHEMICALS CO., LTD. (KR) | 2014-05-06 | — | — | US | claimed |
| EP-2556820-A2 | COMPOSITION CONTAINING PDE5 INHIBITOR FOR RELIEVING SKIN WRINKLES | SK Chemicals, Co., Ltd. (KR) | 2013-02-13 | — | — | EP | claimed |
| US-20130030174-A1 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | SK CHEMICALS CO., LTD. (KR) | 2013-01-31 | — | — | US | claimed |
| US-20060014754-A1 | Methods and compositions for treating diseases and conditions of the eye | PFIZER INC. | 2006-01-19 | — | — | US | claimed |
| US-20030144296-A1 | Daily treatment for erectile dysfunction using a PDE5 inhibitor | LILLY ICOS LLC | 2003-07-31 | — | — | US | claimed |
| US-20030055070-A1 | Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction | HARRISON WILMA (US) | 2003-03-20 | — | — | US | claimed |
| US-20030027824-A1 | Pyrazolopyrimidinones for the treatment of female sexual dysfunction | ELLIS PETER (GB) | 2003-02-06 | — | — | US | claimed |
| US-6492371-B2 | ADMINISTERING THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND THAT INHIBITS CGMP-SPECIFIC PHOSPHODIESTERASE (PDE5) FOR THERAPY OF PARKINSON'S DISEASE | ROYLANCE H H (US) | 2002-12-10 | — | — | US | claimed |
| US-6469016-B1 | VAGINAL, VULVAR AND/OR URETHRAL ADMINISTRATION OF A PHARMACEUTICAL FORMULATION CONTAINING A VASOACTIVE AGENT TO INCREASE VAGINAL LUBRICATION | VIVUS, INC. | 2002-10-22 | — | — | US | claimed |
| US-6469012-B1 | POTENT, SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASES LEAD TO ELEVATED CGMP LEVELS | PFIZER INC | 2002-10-22 | — | — | US | claimed |
| US-20010053780-A1 | Daily treatment for erectile dysfunction using a PDE5 inhibitor | LILLY ICOS LLC, A DELAWARE CORPORATION | 2001-12-20 | — | — | US | claimed |
| US-6225315-B1 | ADMINISTERING A CGMP PDE INHIBITOR. | PFIZER INC | 2001-05-01 | — | — | US | claimed |
| EP-1074258-A2 | Methods and compositions for treating diseases and conditions of the eye | Pfizer Products Inc. (US) | 2001-02-07 | — | — | EP | claimed |
| EP-1022026-A2 | Pharmaceutical compositions for treating nitrate-induced tolerance | Pfizer Limited (GB) | 2000-07-26 | — | — | EP | claimed |
| EP-0702555-B1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE | PFIZER LTD (GB) | 1998-03-11 | — | — | EP | claimed |
| EP-0702555-A1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE | Pfizer Limited (GB) | 1996-03-27 | — | — | EP | claimed |
| EP-0463756-B1 | Pyrazolopyrimidinone antianginal agents | PFIZER LTD (GB) | 1995-04-19 | — | — | EP | claimed |
| WO-1994028902-A1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE | PFIZER LIMITED (GB) | 1994-12-22 | — | — | WO | claimed |
| US-5250534-A | Inhibitors of cyclic guanosine 3*,5*-monophosphate phosphodiesterase | PFIZER INC. (US) | 1993-10-05 | — | — | US | claimed |
| EP-0463756-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1992-01-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027824-A1 | Pyrazolopyrimidinones for the treatment of female sexual dysfunction | FSHR, GNRHR, LHCGR | PDE5A 393/4885PDE3B 308/4885PDE3A 268/4885 |
| US-20030144296-A1 | Daily treatment for erectile dysfunction using a PDE5 inhibitor | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE3B 4/4885PDE3A 2/4885 |
| US-20010053780-A1 | Daily treatment for erectile dysfunction using a PDE5 inhibitor | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE3B 4/4885PDE3A 2/4885 |
| US-20030055070-A1 | Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction | PDE5A, HTR5A, PDE3A | PDE5A 1/4885PDE3B 5/4885PDE3A 3/4885 |
| US-20060014754-A1 | Methods and compositions for treating diseases and conditions of the eye | PDE6C, PDE6D, PDE6A | PDE5A 5/4885PDE3B 9/4885PDE3A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.